

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

September 29, 2017

BSE Limited
1st Floor, P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051

Re.: **Press Release**

Dear Sir / Madam,

We enclose herewith a copy of press release dated September 29, 2017 titled "Zydus receives final approval from the USFDA for Doxycycline Tablets USP".


The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**

for, 
UPEN H. SHAH
COMPANY SECRETARY



Encl.: As above

Zydus receives final approval from the USFDA for Doxycycline Tablets USP

Ahmedabad, 29 September 2017

Zydus Cadila has received the final approval from the USFDA to market Doxycycline Tablets USP in strengths of 50 mg, 75 mg, 100 mg and 150 mg. The drug is a tetracycline antibiotic that fights bacteria in the body and is used to treat many different bacterial infections, such as acne, urinary tract infections, intestinal infections, eye infections, gonorrhoea, chlamydia, periodontitis (gum disease) and others. It will be manufactured at the group's formulations manufacturing facility at the Pharma SEZ, Ahmedabad

The group now has more than 155 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
